STAAR Surgical (STAA) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

STAAR Surgical

NasdaqGM•Healthcare•Medical Instruments & Supplies

$22.66-0.76(-0.03%)Market closed

Market Cap

$1.05B

P/E

272.9x

P/S

3.1x

P/B

2.9x

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

How this company scores

AverageMetricSide Score: 55/100

Strongest: Growth (21/25); weakest: Cash & Earnings Quality (6/25).

Profitability13/25

Growth21/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Growing revenueRising earningsInterest easily coveredProfit converts from growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 272.9x5y range 59.6x – 272.9x

Currently above its 14-quarter median.

P/S · 3.1x5y range 3.1x – 84.9x

Currently below its 20-quarter median.

P/B · 2.9x5y range 2.5x – 24.5x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 6 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $1.05B

Metrics at a Glance

as of July 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $339.59M
Q. Revenue: $93.53M
TTM EBITDA: $23.50M
TTM Op. Income: $13.73M
Q. Op. Income: $10.10M
TTM Net Income: $3.84M
Q. Net Income: $8.06M
EPS: $0.16
Shares Out.: $50.32M

$339.59M in TTM revenue grew 51.3% YoY, reaching $93.53M last quarter. TTM EBITDA of $23.50M and TTM operating income of $13.73M show growth is flowing through to the bottom line. TTM net income of $3.84M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 4 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 74.5%
EBITDA Margin: 14.4%
Op. Margin: 10.8%
Net Margin: 8.6%

Op. margin of 10.8% is up 78.4% YoY — cost efficiency is improving. Net margin at 8.6% and gross margin of 74.5% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 272.9x
P/S Ratio: 3.1x
P/B Ratio: 2.9x

At 272.9x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 3.1x and P/B of 2.9x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is up 0% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $475.20M
Cash: $148.58M
Long-Term Debt: N/A
Book Value: $365.40M
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $19.69M
TTM Free Cash Flow: $-6.75M
FCF Margin: -2.0%
FCF / Net Income: -1.8

TTM FCF of $-6.75M on $19.69M in operating cash flow. The FCF / Net Income ratio of -1.8x means the business consumes cash — it is not yet self-funding. Over the past year, free cash flow is up 85% — an improving trend.